Hancock Jaffe Changes Name To enVVeno, Drops Cardiac Device To Focus On Venous Disease
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
You may also be interested in...
The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.
The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.
Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.